Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 3/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4347014 | 0.95 | HTR2A (0.32) | HTR2ACNR1CNR2KDM1AEZH2 | |
| SCHEMBL3798522 | 0.88 | TRPM8 (0.30) | KDM1A | |
| SCHEMBL617187 | 0.82 | TRPM8 (0.36) | HTR2ACNR1CNR2EZH2 | |
| SCHEMBL919159 | 0.79 | TRPM8 (0.38) | HTR2AKDM1A | |
| SCHEMBL3797219 | 0.79 | TRPM8 (0.38) | HTR2AKDM1A | |
| SCHEMBL3800669 | 0.79 | TRPM8 (0.38) | HTR2AKDM1A | |
| SCHEMBL3582825 | 0.78 | CNR1 (0.45) | HTR2ACNR1CNR2 | |
| Hydrochloric Acid SCHEMBL13516693 | 0.78 | TRPM8 (0.38) | HTR2AKDM1A | |
| SCHEMBL11480145 | 0.78 | TRPM8 (0.35) | HTR2ACNR1CNR2EZH2 | |
| SCHEMBL3794807 | 0.76 | TRPV3 (0.38) | HTR2ACNR1CNR2KDM1ANOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| EP-1931681-B1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS SA (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| US-7842703-B2 | Substituted benzofused derivatives and their use as vanilloid receptor ligands | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1931681-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Glenmark Pharmaceuticals S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007042906-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | HTR2A 85/4885CNR1 79/4885CNR2 55/4885 |
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | TRPV1, GPR17, TRPV6 | HTR2A 279/4885CNR1 30/4885CNR2 41/4885 |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | HTR2A 248/4885CNR1 34/4885CNR2 41/4885 |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | HTR2A 248/4885CNR1 34/4885CNR2 41/4885 |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | HTR2A 279/4885CNR1 30/4885CNR2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.